MedTrace Logo

Annexin A5 in Patients With Severe COVID-19 Disease

NCT04748757 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-03-08

No results posted yet for this study

Summary

Randomized, double-blind, placebo-controlled trial comparing 2 doses of SY-005 (recombinant human Annexin A5) to placebo in patients with severe coronavirus 2019 disease in a single hospital centre with 2 intensive care units

Conditions

  • Coronavirus Infection
  • Sepsis

Interventions

DRUG

recombinant human annexin A5

recombinant human annexin A5, manufactured as SY-005

DRUG

Placebo

Normal saline 50 ml

Sponsors & Collaborators

  • Ontario Ministry of Colleges and Universities

    collaborator UNKNOWN

  • London Health Sciences Foundation

    collaborator UNKNOWN

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Claudio Martin, MD, MSc · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-20
Primary Completion
2022-04-03
Completion
2022-12-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04748757 on ClinicalTrials.gov